From July 6 to 9, 2026, the Beninese Agency for Medicines and Health Products (ABMed) underwent a rigorous assessment led by a panel of World Health Organization (WHO) experts. This in-depth evaluation highlighted remarkable advancements, positioning Benin on the brink of achieving the coveted WHO Maturity Level 3 certification—a milestone that would cap nearly a decade of sweeping reforms in the country’s healthcare sector.
An intensive WHO evaluation of Benin’s pharmaceutical framework
A high-level delegation of eight international WHO specialists spent four days meticulously reviewing Benin’s regulatory systems. Every facet of ABMed’s operations was scrutinized, from drug market authorization and post-market surveillance to pharmacovigilance and clinical trial oversight. The audit’s primary goal was to assess how closely the agency’s processes aligned with the world’s most stringent pharmaceutical standards.
The findings, presented in Cotonou on July 9, 2026, revealed encouraging progress. The evaluation confirmed significant strides in strengthening the country’s supply chain security for health products, marking a critical step forward in ensuring safe, high-quality medicines for the population.
The significance of WHO Maturity Level 3 for Benin
What does WHO Maturity Level 3 mean for Benin? In the organization’s classification system, this status identifies countries with a stable, fully integrated pharmaceutical regulatory system capable of exerting complete control over medications circulating within their borders. Achieving this level ensures that citizens have reliable access to safe, effective, and high-quality health products.
Beyond safety, this WHO certification carries substantial economic and geopolitical advantages. It enhances international trust, boosts local drug production, and simplifies exports to neighboring markets. For Beninese citizens, it represents a powerful defense against counterfeit medicines—a persistent public health threat.
A decade of reforms reaching fruition
The evaluation’s results were unveiled in the presence of Health Minister Professor Benjamin Hounkpatin, who expressed deep satisfaction with the progress. In his address, he commended the ABMed team for their dedication and the transformative changes implemented over the years.
The imminent recognition is no accident—it reflects the government’s bold, systematic reforms in the pharmaceutical sector since 2017. By transforming the former pharmacy directorate into an autonomous agency (ABMed) and strengthening legal frameworks, Benin laid the groundwork for this achievement. Minister Hounkpatin reaffirmed the state’s unwavering commitment to supporting ABMed until the certification is formally secured.
Benin poised to lead West Africa’s pharmaceutical sector
This evaluation’s implications extend far beyond Benin’s borders. If the final assessment confirms the shift to Maturity Level 3, Benin will become the second Francophone nation in West Africa to reach this global benchmark, trailing only Senegal.
This milestone would position Benin as a regional hub for pharmaceutical excellence, proving that with strong political will and technical rigor, African nations can elevate their institutions to meet the world’s highest standards.
A new era for public health in Benin
The July 2026 WHO mission marks a historic turning point for Benin’s health sector. While indicators are promising, the ABMed team must now sustain momentum, implementing the final recommendations to officially attain this certification. By inching closer to Maturity Level 3, Benin demonstrates that patient safety and pharmaceutical sovereignty are no longer distant goals—but an imminent reality.